Novo Nordisk A/S reclaimed its position as Europe’s most valuable public company, overtaking software developer SAP SE.
Shares in the Danish drugmaker climbed as much as 2.3% on Friday after Novo said it plans to advance its experimental weight management treatment amycretin into late-stage development following feedback from regulatory authorities.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.